Charles River Laboratories and Genetic Cures for Kids Inc (GC4K), an Australian foundation focused on research programs and clinical trials to find cures for rare diseases, entered a plasmid DNA contract development and manufacturing collaboration.   Founded in 2021, GC4K’s mission is to develop a gene therapy for the treatment of Hereditary Spastic Paraplegia Type 56 (SPG56), a debilitating neurodegenerative disease that that impacts the ability to walk, talk, and move independently.   GC4K...